Moderna’s Updated COVID-19 Vaccine Close to FDA Filing
August 24, 2022
Trending News 🌥️
Moderna($NASDAQ:MRNA) is on the verge of filing data with the FDA that would pave the way for emergency use authorization of an updated COVID-19 vaccine. This new version of the vaccine is designed to protect against the BA.4 and BA.5 Omicron subvariants, which are currently the dominant strains in the US. It’s unclear how this will affect Moderna’s market and earnings in the long term.
However, if the vaccine is approved, it would likely boost demand for Moderna’s products in the short term.
Share Price
Moderna’s stock opened at $141.7 on Tuesday and closed at $143.8, up 0.9% from its previous closing price of $142.5. The new vaccine is more effective than the original version and has been shown to be effective against variants of the virus. Moderna is confident that the FDA will approve the new vaccine and intends to file for approval in the coming weeks.
VI Analysis
The company’s fundamentals reflect its long term potential, but there are potential risks in the business and financial areas. The VI app makes it easy to see where these risks are and how they could impact the company’s future. Based on the VI Risk Rating, MODERNA is a high risk investment in terms of financial and business aspects.
However, the company’s strong fundamentals suggest that it has the potential to overcome these risks and continue to grow in the future.
Summary
This news is good for investors because it means that the company is making progress in its efforts to create a safe and effective vaccine. The FDA approval process can take several months, so the sooner Moderna can file its application, the better.
